Ernexa Therapeutics Inc.

ERNA Healthcare Biotechnology

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−70.69
Beneish M
−24.48
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Jan '22 Dec '21 Jan '21 Dec '20 Jan '20 Dec '19
Total current assets
3.13 2.35 9.60 13.68 — 18.77 — 1.73 — 6.07
Total non-current assets
2.70 2.92 39.53 8.60 — 12.76 — 11.17 — 8.06
Total Assets
5.83 5.27 49.13 22.28 — 31.53 — 12.91 — 14.13
Total current liabilities
3.11 2.94 6.57 7.65 — 3.68 — 3.13 — 6.10
Total non-current liabilities
0.32 0.63 40.33 2.52 — 2.35 — 2.12 — 2.94
Total liabilities
3.43 3.57 46.90 10.17 — 6.02 — 5.25 — 9.03
Common Equity (Total)
2.40 1.70 2.23 12.11 — 25.50 — 7.66 — 5.09
Shareholders Equity (Total)
2.40 1.70 2.23 12.11 — 25.50 — 7.66 — 5.09
Total Debt
— — 6.77 — 0.89 — 2.30 0.31 2.90 2.76

Show all line items

In millions of $ except per-share values · columns are period end dates